Fusion Antibodies has provided an update on its AI/ML-AbTM antibody discovery service. The company has developed an artificial intelligence and machine learning platform that enables the rapid discovery of high-quality antibodies. This platform utilizes advanced algorithms to analyze large datasets and identify potential therapeutic antibodies. Fusion Antibodies has successfully applied this technology to various projects, including the development of antibodies for COVID-19. The company believes that the AI/ML-AbTM platform will significantly enhance its antibody discovery capabilities and accelerate the development of novel therapeutics.